The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | LB1908: a novel CAR-T cell therapy targeting claudin 18.2 in GI malignancies
David Bing Zhen, MD, University of Washington Medicine, Seattle, WA, provides an overview of an open-label, Phase I trial (NCT05539430) of LB1908, an anti-claudin 18.2 CAR-T cell therapy, in patients with locally advanced and metastatic gastric, esophageal, gastroesophageal junction cancers. The first portion of the trial will assess safety and the recommended dose, whereas the second portion will involve dose expansion and include patients with pancreatic adenocarcinomas. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
